Eastwood Bio-Medical Canada Inc.

EBM

CA27783W1059

Pharmaceuticals

Delayed Toronto S.E. Other stock markets 09:52:23 2024-05-13 EDT			5-day change	1st Jan Change
0.55 ^CAD	-37.50%		-37.50%	0.00%

04-02	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	CI
02-29	Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	CI

Eastwood Bio-Medical Canada Inc. Appoints Youngsoo Kim as the New Chief Executive Officer

September 03, 2020

Eastwood Bio-Medical Canada Inc. announced the appointment of Dr. Youngsoo Kim as the new Chief Executive Officer. Kim is the founder of Eastwood Bio-Medical Research Inc., the former parent company of the Company.

Latest news about Eastwood Bio-Medical Canada Inc.

Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024	04-02	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2023	02-28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2023	23-09-29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2023	23-06-30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2023	23-03-31	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	23-02-27	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2022	23-02-27	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2022	22-09-29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2022	22-06-29	CI
Eastwood Bio-Medical Canada Inc.(TSXV:EBM) dropped from S&P/TSX Venture Composite Index	22-04-18	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2022	22-04-01	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2021	22-02-28	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	22-02-27	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2021	21-09-28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2021	21-06-29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2020	21-03-01	CI
Eastwood Bio-Medical Canada Inc. Auditor Raises 'Going Concern' Doubt	21-02-28	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Third Quarter Ended July 31, 2020	20-09-29	CI
Eastwood Bio-Medical Canada Inc. Appoints Youngsoo Kim as the New Chief Executive Officer	20-09-03	CI
Eastwood Bio-Medical Canada Inc. Announces Executive Change	20-09-03	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Second Quarter Ended April 30, 2020	20-06-29	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the First Quarter Ended January 31, 2020	20-03-30	CI
Eastwood Bio-Medical Canada Inc. Reports Earnings Results for the Full Year Ended October 31, 2019	20-02-26	CI
Eastwood Bio-Medical Canada Inc. Partners with Ruiyan	20-01-22	CI
Eastwood Bio-Medical Canada Inc. Introduces New Products	19-10-07	CI

Chart Eastwood Bio-Medical Canada Inc.

Duration

Period

More charts

Company Profile

Eastwood Bio-Medical Canada Inc. is engaged in marketing and distributing natural health products in North America. It is a licensed distributor of the Eleotin line of products, which include formulations based on natural ingredients that are presented in tea or capsule forms. The Eleotin products include natural remedies for certain metabolic disorders such as blood glucose disorders, hypertension and obesity, and can be used as a dietary supplement. Its licensed products include Eleotin A 700, which is a treatment for spleen deficiency, lack of appetite and fatigue; Eleotin AL88, a laxative; Eleotin Cal20, for bone and teeth maintenance; Eleotin V3D, for the development and maintenance of bones, teeth and good health; Eleotin G2000, for cardiovascular health; Eleotin H55, for sedative and tension relief, and Eleotin Zn330, for the tissue formation and metabolism. In addition, it offers Eleotin Bentley to promote healthy glucose levels and Eleotin LBM for hypertension relief.

Sector

Pharmaceuticals

Calendar

2024-06-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Alternative Medicine

	1st Jan change	Capi.
EASTWOOD BIO-MEDICAL CANADA INC.	0.00%	27.83M
DONG-E-E-JIAO CO.,LTD.	+42.38%	6.28B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.86%	4.51B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.36%	3.35B
TASLY PHARMACEUTICAL GROUP CO., LTD	-11.28%	3.13B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.23%	2.47B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.24%	1.96B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.98%	1.63B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-11.32%	1.56B

Alternative Medicine